Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TNFR2 is critical for TNF-induced rheumatoid arthritis fibroblast-like synoviocyte inflammation.
Suto T, Tosevska A, Dalwigk K, Kugler M, Dellinger M, Stanic I, Platzer A, Niederreiter B, Sevelda F, Bonelli M, Pap T, Kiener H, Okamura K, Chikuda H, Aletaha D, Heinz LX, Karonitsch T. Suto T, et al. Among authors: heinz lx. Rheumatology (Oxford). 2022 Nov 2;61(11):4535-4546. doi: 10.1093/rheumatology/keac124. Rheumatology (Oxford). 2022. PMID: 35258553
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
Mrak D, Tobudic S, Koblischke M, Graninger M, Radner H, Sieghart D, Hofer P, Perkmann T, Haslacher H, Thalhammer R, Winkler S, Blüml S, Stiasny K, Aberle JH, Smolen JS, Heinz LX, Aletaha D, Bonelli M. Mrak D, et al. Among authors: heinz lx. Ann Rheum Dis. 2021 Oct;80(10):1345-1350. doi: 10.1136/annrheumdis-2021-220781. Epub 2021 Jul 20. Ann Rheum Dis. 2021. PMID: 34285048
Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial.
Bonelli M, Mrak D, Tobudic S, Sieghart D, Koblischke M, Mandl P, Kornek B, Simader E, Radner H, Perkmann T, Haslacher H, Mayer M, Hofer P, Redlich K, Husar-Memmer E, Fritsch-Stork R, Thalhammer R, Stiasny K, Winkler S, Smolen JS, Aberle JH, Zeitlinger M, Heinz LX, Aletaha D. Bonelli M, et al. Among authors: heinz lx. Ann Rheum Dis. 2022 May;81(5):687-694. doi: 10.1136/annrheumdis-2021-221558. Epub 2022 Jan 13. Ann Rheum Dis. 2022. PMID: 35027397 Clinical Trial.
Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study.
Mrak D, Simader E, Sieghart D, Mandl P, Radner H, Perkmann T, Haslacher H, Mayer M, Koblischke M, Hofer P, Göschl L, Kartnig F, Deimel T, Kerschbaumer A, Hummel T, Kornek B, Thalhammer R, Stiasny K, Winkler S, Smolen JS, Aberle JH, Aletaha D, Heinz LX, Bonelli M. Mrak D, et al. Among authors: heinz lx. Ann Rheum Dis. 2022 Dec;81(12):1750-1756. doi: 10.1136/ard-2022-222579. Epub 2022 Aug 17. Ann Rheum Dis. 2022. PMID: 35977809
Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial.
Mrak D, Sieghart D, Simader E, Tobudic S, Radner H, Mandl P, Göschl L, Koblischke M, Hommer N, Wagner A, Mayer M, Schubert L, Hartl L, Kozbial K, Hofer P, Kartnig F, Hummel T, Kerschbaumer A, Deimel T, Puchner A, Gudipati V, Thalhammer R, Munda P, Uyanik-Ünal K, Zuckermann A, Novacek G, Reiberger T, Garner-Spitzer E, Reindl-Schwaighofer R, Kain R, Winkler S, Smolen JS, Stiasny K, Fischer GF, Perkmann T, Haslacher H, Zeitlinger M, Wiedermann U, Aberle JH, Aletaha D, Heinz LX, Bonelli M. Mrak D, et al. Among authors: heinz lx. Nat Commun. 2022 Sep 12;13(1):5362. doi: 10.1038/s41467-022-33036-y. Nat Commun. 2022. PMID: 36097029 Free PMC article. Clinical Trial.
Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls.
Kartnig F, Mrak D, Simader E, Tobudic S, Radner H, Mandl P, Göschl L, Hommer N, Mayer M, Hofer P, Hummel T, Deimel T, Geßl I, Puchner A, Kerschbaumer A, Thalhammer R, Handisurya A, Kain R, Winkler S, Smolen JS, Stiasny K, Perkmann T, Haslacher H, Aberle JH, Aletaha D, Heinz LX, Sieghart D, Bonelli M. Kartnig F, et al. Among authors: heinz lx. Ann Rheum Dis. 2023 Feb;82(2):292-300. doi: 10.1136/ard-2022-222682. Epub 2022 Sep 15. Ann Rheum Dis. 2023. PMID: 36109141 Clinical Trial.
Cytokine-directed cellular cross-talk imprints synovial pathotypes in rheumatoid arthritis.
Kugler M, Dellinger M, Kartnig F, Müller L, Preglej T, Heinz LX, Simader E, Göschl L, Puchner SE, Weiss S, Shaw LE, Farlik M, Weninger W, Superti-Furga G, Smolen JS, Steiner G, Aletaha D, Kiener HP, Lewis MJ, Pitzalis C, Tosevska A, Karonitsch T, Bonelli M. Kugler M, et al. Among authors: heinz lx. Ann Rheum Dis. 2023 Sep;82(9):1142-1152. doi: 10.1136/ard-2022-223396. Epub 2023 Jun 21. Ann Rheum Dis. 2023. PMID: 37344156
The Lipid-Modifying Enzyme SMPDL3B Negatively Regulates Innate Immunity.
Heinz LX, Baumann CL, Köberlin MS, Snijder B, Gawish R, Shui G, Sharif O, Aspalter IM, Müller AC, Kandasamy RK, Breitwieser FP, Pichlmair A, Bruckner M, Rebsamen M, Blüml S, Karonitsch T, Fauster A, Colinge J, Bennett KL, Knapp S, Wenk MR, Superti-Furga G. Heinz LX, et al. Cell Rep. 2015 Jun 30;11(12):1919-28. doi: 10.1016/j.celrep.2015.05.006. Epub 2015 Jun 18. Cell Rep. 2015. PMID: 26095358 Free PMC article.
A conformation-locking inhibitor of SLC15A4 with TASL proteostatic anti-inflammatory activity.
Boeszoermenyi A, Bernaleau L, Chen X, Kartnig F, Xie M, Zhang H, Zhang S, Delacrétaz M, Koren A, Hopp AK, Dvorak V, Kubicek S, Aletaha D, Yang M, Rebsamen M, Heinz LX, Superti-Furga G. Boeszoermenyi A, et al. Among authors: heinz lx. Nat Commun. 2023 Oct 20;14(1):6626. doi: 10.1038/s41467-023-42070-3. Nat Commun. 2023. PMID: 37863876 Free PMC article.
38 results